Answers are grounded in this paper and cite their sources.
Aim: To evaluate the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents on the development of sustained ocular hypertension (OHT) in patients with neovascular age-related macular degeneration (AMD). Methods: A retrospective study of patients with neo- vascular AMD who received unilateral intravitreal anti-VEGF treatment was performed. Fellow non-injected eyes were used as controls. Initial intraocular pressure (IOP) was measured before the first injection and final IOP was measured 3-4 weeks after the last injection. Eyes that re- quired IOP lowering treatment during follow-up were identified. Results: Seventy-two patients were eligible for the study. Sustained ocular hypertension (OHT) developed in 3 (4.2%) of the injected eyes and in 1 (1.4%) of controls. There was no statistically significant difference be- tween final IOP in the study and control groups. In the study group, patients who received >20 anti-VEGF injections showed a significantly larger variation of IOP during follow-up (p=0.034) Conclusion: Eyes receiving a higher number of injections suffer a significantly larger IOP varia- tion than eyes treated with fewer injections, but larger studies are needed to conclude if treatment with intravitreal anti-VEGF agents increases the risk of developing sustained OHT.
No takes yet. Share an insight, caveat, or question.
Beato et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: